Rapport Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a collaboration revenue of $20 million, attributed to a non-refundable upfront payment from its recent licensing agreement with Tenacia Biotechnology. This marks a significant increase compared to the same period in 2025, when the company reported no revenue. The net loss for the quarter was $19.9 million, a decrease from the $24.1 million loss reported in the prior year, reflecting improved operational efficiency despite ongoing investments in research and development.
Total operating expenses for the first quarter of 2026 were $44.2 million, up from $27.1 million in the same quarter of 2025. The increase was primarily driven by a $13.1 million rise in research and development expenses, which reached $32.7 million, largely due to costs associated with the ongoing clinical trials for RAP-219, the company's lead product candidate. General and administrative expenses also rose to $11.5 million, up from $7.5 million, reflecting higher personnel costs and professional fees related to the Tenacia agreement.
In terms of operational metrics, Rapport Therapeutics has made significant strides in its clinical programs. The company is advancing RAP-219 through late-stage clinical trials, with plans to initiate Phase 3 trials for drug-resistant focal onset seizures in the second quarter of 2026. Additionally, the company is expanding its epilepsy portfolio to include primary generalized tonic-clonic seizures and is progressing with a Phase 2 trial for bipolar mania, with topline results expected in late 2026.
As of March 31, 2026, Rapport Therapeutics had cash, cash equivalents, and short-term investments totaling $476.8 million, providing a solid financial foundation to support its ongoing clinical development and operational needs. The company anticipates that its existing resources will be sufficient to fund operations into the second half of 2029. However, it acknowledges the need for additional financing to support its growth strategy, particularly as it continues to incur significant operating losses while pursuing regulatory approvals for its product candidates.
Looking ahead, Rapport Therapeutics remains focused on advancing its clinical programs and expanding its pipeline of precision medicines for neurological and psychiatric disorders. The company is committed to leveraging its RAP technology platform to develop innovative therapies that address unmet medical needs, while also navigating the complexities of drug development and regulatory processes.
About Rapport Therapeutics, Inc.
Rapport Therapeutics is a biotech company focused on developing small molecule precision medicines for neurological and psychiatric disorders. Its platform targets neuronal receptor complexes, such as TARP-8 and nAChRs, to create highly selective therapies with improved safety profiles. The company’s lead candidate, RAP-219, aims to treat focal epilepsy, bipolar disorder, and neuropathic pain by precisely modulating brain region-specific receptors, reducing side effects and drug interactions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.